THE LEADING RESEARCH REPORTS DISTRIBUTION
NETWORK

icrowd research  icrowd research  icrowd research  icrowd research  icrowd research  icrowd research  icrowd research  icrowd research icrowd research

Intravenous Immunoglobulin Market Growth, Size, Analysis, Outlook by 2017 – Trends, Opportunities and Forecast to 2024

Oct 29, 2018 10:26 AM ET

Intravenous Immunoglobulin Market Size is anticipated to reach over USD 16,882.15 Million by 2026, according to a new research published by Polaris Market Research.

Intravenous Immunoglobulin Market majorly is driven by rising elderly population, increasing occurrence of immunodeficiency disorders, growing implementation of IVIG procedures and increasing usage of off-label indications. Increasing number of patients with immunodeficiency disease is the primary reason for the expansion of IVIG procedures. According to the World Health Organization (WHO), there are approximately 50 diverse Primary Immune Deficiency (PID) such as X-lined hypo-gamma-globulinemia, specific antibody deficiency and others.

Request PDF Brochure for this Research Insights @

http://bit.ly/2Av2WOD

Some major key players in Intravenous Immunoglobulin Market includes: –

  • Baxter International Inc.
  • CSL Ltd.,
  • Grifols S.A
  • Octapharma AG
  • Kedrion Biopharma Inc.
  • LFB group
  • Biotest AG
  • China Biologics Product Inc.
  • BDI Pharma Inc.
  • Bayer Healthcare.

According to the U.S. National Library of Medicine and National Institute of Health, around 6 million patients are suffering from PID globally. Rising occurrences of these immune diseases is anticipated to bolster the demand for Intravenous Immunoglobulin treatments during the forecast period. The demand for IVIG treatments for the primary and acquired immunodeficiency disorder is growing as it is the only available as well as most effective treatment option. Moreover, inactive lifestyle behaviors, including intake of saturated fats, sugars and salts, less physical actions, and high alcohol intake have led to the surge in the occurrence of such diseases. Increasing occurrence of such lifestyle related disease including antibody deficiency disorders and obesity are the factors anticipated to drive the Intravenous Immunoglobulin Market growth.

Make an Enquiry Before Buying this report: –

http://bit.ly/2AtPs5Q

On the basis of application, Intravenous Immunoglobulin Market is categorized into Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Hypogammaglobulinemia, Congenital AIDS, Immunodeficiency diseases, Multifocal motor neuropathy, Myasthenia Gravis, Chronic Lymphocytic Leukemia, Kawasaki disease, Guillain-Barre syndrome, and Idiopathic Thrombocytopenic Purpura (ITP). In 2017, Hypogammaglobulinemia is estimated to dominate the application segment. The dominancy is attributed to the growing global occurrences of primary immunodeficiency diseases (PID). It is the most common chronic immune defect in patients with lymphoproliferative disorders (LPDs). According to the Centers for Disease Control and Prevention (CDC) in 2012, the global occurrence rate of hypogammaglobulinemia was around 2 per 100,000 populations moreover, the number of people suffering this type of disease are estimated to increase during the forecast period. Growing occurrence of immunodeficiency disorders associated with the high implementation of IVIG therapies is expected to drive the segment growth significantly.

TOC of Intravenous Immunoglobulin Market:

Chapter 1. Overview and Scope

Chapter 2. Market Summary

Chapter 3 Intravenous Immunoglobulin Market Size and Forecast

Chapter 4. Dynamics and Segmentation

Chapter 5. Detailed Insight on Key Company

Chapter 6. Research Methodology and Reference

Chapter 7. Competitive Landscape

TOC Continued……!!!

See Campaign: https://www.polarismarketresearch.com
Contact Information:
bitumen market

Tags:
Research, Wire, Research Newswire, South America, North America, United States, Latin America, United Kingdom, Europe, Africa, Asia, Middle East, English

image